Doxazocin in management of benign prostatic hyperplasia

A total 220 patients with benign prostatic hyperplasia (BPH) but not having absolute indication for surgery were enrolled for 8 weeks single label study, using doxazocin (Doxacard) 4 mg daily for their features of prostatism, with a six month follow up. The study revealed an improve-ment of 90% in t...

Full description

Bibliographic Details
Main Authors:	N K Mohanty, R P Arora, A K Jha, S Singh Pal
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2003-01-01
Series:	Indian Journal of Urology
Subjects:	α - alderneric doxazocin Doxacard.
Online Access:	http://www.indianjurol.com/article.asp?issn=0970-1591;year=2003;volume=19;issue=2;spage=113;epage=116;aulast=Mohanty

id	doaj-3aad95378774467794837abf371504b3
record_format	Article
spelling	doaj-3aad95378774467794837abf371504b32020-11-24T23:23:56ZengWolters Kluwer Medknow PublicationsIndian Journal of Urology0970-15911998-38242003-01-01192113116Doxazocin in management of benign prostatic hyperplasiaN K MohantyR P AroraA K JhaS Singh PalA total 220 patients with benign prostatic hyperplasia (BPH) but not having absolute indication for surgery were enrolled for 8 weeks single label study, using doxazocin (Doxacard) 4 mg daily for their features of prostatism, with a six month follow up. The study revealed an improve-ment of 90% in their symptoms at the end of the study with an increase of maximum flow rate (MFR) by 5-5.5 ml/sec and average flow rate (AFR) 2.5-3 ml/sec. Adverse effects were minimum and patient compliance was very good with good drug tolerability. Our study strongly supports the use of doxazocin as an alternative in the management of uncomplicated BPH with hypertension.http://www.indianjurol.com/article.asp?issn=0970-1591;year=2003;volume=19;issue=2;spage=113;epage=116;aulast=Mohantyα - aldernericdoxazocinDoxacard.
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	N K Mohanty R P Arora A K Jha S Singh Pal
spellingShingle	N K Mohanty R P Arora A K Jha S Singh Pal Doxazocin in management of benign prostatic hyperplasia Indian Journal of Urology α - alderneric doxazocin Doxacard.
author_facet	N K Mohanty R P Arora A K Jha S Singh Pal
author_sort	N K Mohanty
title	Doxazocin in management of benign prostatic hyperplasia
title_short	Doxazocin in management of benign prostatic hyperplasia
title_full	Doxazocin in management of benign prostatic hyperplasia
title_fullStr	Doxazocin in management of benign prostatic hyperplasia
title_full_unstemmed	Doxazocin in management of benign prostatic hyperplasia
title_sort	doxazocin in management of benign prostatic hyperplasia
publisher	Wolters Kluwer Medknow Publications
series	Indian Journal of Urology
issn	0970-1591 1998-3824
publishDate	2003-01-01
description	A total 220 patients with benign prostatic hyperplasia (BPH) but not having absolute indication for surgery were enrolled for 8 weeks single label study, using doxazocin (Doxacard) 4 mg daily for their features of prostatism, with a six month follow up. The study revealed an improve-ment of 90% in their symptoms at the end of the study with an increase of maximum flow rate (MFR) by 5-5.5 ml/sec and average flow rate (AFR) 2.5-3 ml/sec. Adverse effects were minimum and patient compliance was very good with good drug tolerability. Our study strongly supports the use of doxazocin as an alternative in the management of uncomplicated BPH with hypertension.
topic	α - alderneric doxazocin Doxacard.
url	http://www.indianjurol.com/article.asp?issn=0970-1591;year=2003;volume=19;issue=2;spage=113;epage=116;aulast=Mohanty
work_keys_str_mv	AT nkmohanty doxazocininmanagementofbenignprostatichyperplasia AT rparora doxazocininmanagementofbenignprostatichyperplasia AT akjha doxazocininmanagementofbenignprostatichyperplasia AT ssinghpal doxazocininmanagementofbenignprostatichyperplasia
_version_	1725562706080038912

Doxazocin in management of benign prostatic hyperplasia

Similar Items